...
首页> 外文期刊>The Prostate >Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
【24h】

Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.

机译:人激肽释放酶基因14(KLK14)在正常和癌性前列腺组织中的差异表达。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Many members of the human kallikrein gene family are differentially expressed in cancer and a few have potential as diagnostic/prognostic markers. KLK14 is a newly discovered human kallikrein gene that is mainly expressed in the central nervous system and endocrine tissues. Since KLK14 was found to be regulated by steroid hormones in prostate cancer cell lines, we hypothesized that it will be differentially expressed in prostate cancer tissues compared to their normal counterparts. METHODS: Matched prostate tissue samples from the cancerous and non-cancerous parts of the same prostates were obtained from 100 patients who underwent radical prostatectomy. Quantitative analysis of KLK14 expression levels were performed by real-time RT-PCR using SYBR Green I dye on the LightCycler trade mark system. Associations with clinico-pathological parameters were analyzed. RESULTS: KLK14 overexpression in the cancerous compared to non-cancerous tissue was found in 74% of patients (P < 0.001). Mean level of expression was 154 arbitrary units (Au) in cancerous tissues and 14.2 Au in the non-cancerous tissues. The ratio of the cancerous to non-cancerous KLK14 expression values was higher in patients with late stage (stage III) compared to stage II (P = 0.002), and in grade 3 compared to grade 1/2 tumors (P = 0.001). A statistically significant increase was also observed in patients with higher in Gleason score (>6) compared to Gleason score = 6 tumors (P = 0.027). No correlation was found between KLK14 tissue expression levels and serum prostate-specific antigen. CONCLUSIONS: KLK14 expression is significantly higher in cancerous compared to non-cancerous prostatic tissue. The up-regulation of the KLK14 gene in advanced and more aggressive tumors may indicate a possible role for the hK14 protein in tumor spread and opens the possibility of hK14 being a candidate new marker for prostate cancer diagnosis and prognosis. Prostate 56: 287-292, 2003.
机译:背景:人类激肽释放酶基因家族的许多成员在癌症中差异表达,少数具有作为诊断/预后标志物的潜力。 KLK14是新发现的人类激肽释放酶基因,主要在中枢神经系统和内分泌组织中表达。由于发现KLK14在前列腺癌细胞系中受类固醇激素调节,因此我们假设与正常的前列腺癌组织相比,KLK14在前列腺癌组织中会差异表达。方法:从100例行根治性前列腺切除术的患者中,从相同前列腺癌的癌变部位和非癌变部位中提取匹配的前列腺组织样本。使用LightCycler商标系统上的SYBR Green I染料通过实时RT-PCR对KLK14表达水平进行定量分析。分析与临床病理参数的关联。结果:与非癌组织相比,在癌组织中KLK14过表达的比例为74%(P <0.001)。在癌组织中的平均表达水平为154个任意单位(Au),在非癌组织中的平均表达水平为14.2 Au。晚期(III期)患者的癌与非癌性KLK14表达值之比高于II期(P = 0.002),而3级患者则比1/2级肿瘤(P = 0.001)更高。与格里森评分= 6个肿瘤(P = 0.027)相比,格里森评分较高(> 6)的患者也观察到统计学上的显着增加。在KLK14组织表达水平和血清前列腺特异性抗原之间未发现相关性。结论:与非癌性前列腺组织相比,KLK14在癌性组织中的表达明显更高。 KLK14基因在晚期和更具侵袭性的肿瘤中的上调可能表明hK14蛋白在肿瘤扩散中的可能作用,并打开了hK14作为前列腺癌诊断和预后的候选新标记的可能性。前列腺56:287-292,2003年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号